Browse EV MemProt Atlas
- Frequency:
- literature support frequency.
- EVMP score:
annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| GP107 | Q5VW38 | Protein GPR107 (Lung seven transmembrane receptor 1) | Predicted membrane proteinsTransporters | 7 | Adhesion and uptake mediationFusion and delivery mediation | 6 | 0.38 | |||
| LRC4B | Q9NT99 | Leucine-rich repeat-containing protein 4B (Netrin-G3 ligand) (NGL-3) | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 1 | Adhesion and uptake mediation | 6 | 0.38 | |||
| LRC8C | Q8TDW0 | Volume-regulated anion channel subunit LRRC8C (Factor for adipocyte differentiation 158) (Leucine-rich repeat-containing protein 8C) | Predicted membrane proteinsTransporters | 4 | Fusion and delivery mediation | 6 | 0.38 | |||
| NTRI | Q9P121 | Neurotrimin (hNT) (IgLON family member 2) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | Metabolism mediation | 6 | 0.38 | ||||
| PCD18 | Q9HCL0 | Protocadherin-18 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediation | 6 | 0.38 | |||
| RHDF2 | Q6PJF5 | Inactive rhomboid protein 2 (iRhom2) (Rhomboid 5 homolog 2) (Rhomboid family member 2) (Rhomboid veinlet-like protein 5) (Rhomboid veinlet-like protein 6) | Disease related genesEnzymesPotential drug targetsPredicted intracellular proteinsPredicted membrane proteins | 7 | Skin diseaseSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 6 | 0.38 | ||
| ADH1G | P00326 | Alcohol dehydrogenase 1C (EC 1.1.1.1) (Alcohol dehydrogenase subunit gamma) | EnzymesFDA approved drug targetsHuman disease related genesMetabolic proteinsPlasma proteinsPredicted intracellular proteins | Clinical-translation mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.38 | ||||
| ARHG6 | Q15052 | Rho guanine nucleotide exchange factor 6 (Alpha-Pix) (COOL-2) (PAK-interacting exchange factor alpha) (Rac/Cdc42 guanine nucleotide exchange factor 6) | Cancer-related genesPredicted intracellular proteins | Receptor-signaling mediation | 5 | 0.38 | ||||
| CD33 | P20138 | Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33) | CD markersFDA approved drug targetsPlasma proteinsPredicted membrane proteins | 1 | Acute myeloid leukaemiaAlzheimer diseaseBCR-ABL1-negative chronic myeloid leukaemiaLeukaemiaMalignant haematopoietic neoplasmMastocytosisMultiple myelomaMyelodysplastic syndrome | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.38 | ||
| CRLF2 | Q9HC73 | Cytokine receptor-like factor 2 (Cytokine receptor-like 2) (IL-XR) (Thymic stromal lymphopoietin protein receptor) (TSLP receptor) | 1 | Asthma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.38 | |||
| FLNA | P21333 | Filamin-A (FLN-A) (Actin-binding protein 280) (ABP-280) (Alpha-filamin) (Endothelial actin-binding protein) (Filamin-1) (Non-muscle filamin) | Disease related genesHuman disease related genesPlasma proteinsPotential drug targetsPredicted intracellular proteinsTransporters | Alzheimer disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.38 | |||
| ICOS | Q9Y6W8 | Inducible T-cell costimulator (Activation-inducible lymphocyte immunomediatory molecule) (CD antigen CD278) | CD markersDisease related genesHuman disease related genesPredicted membrane proteins | 1 | Lupus erythematosusSolid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationImmune mediationReceptor-signaling mediation | 5 | 0.38 | ||
| KPCA | P17252 | Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13) | Cancer-related genesEnzymesFDA approved drug targetsPlasma proteinsPredicted intracellular proteinsRAS pathway related proteins | Human immunodeficiency virus diseaseMuscular atrophyNephritic syndromeTransplant rejection | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.38 | |||
| LRC15 | Q8TF66 | Leucine-rich repeat-containing protein 15 (Leucine-rich repeat protein induced by beta-amyloid homolog) (hLib) | Plasma proteinsPredicted membrane proteinsTransporters | 1 | Fusion and delivery mediation | 5 | 0.38 | |||
| MSLN | Q13421 | Mesothelin (CAK1 antigen) (Pre-pro-megakaryocyte-potentiating factor) [Cleaved into: Megakaryocyte-potentiating factor (MPF); Mesothelin, cleaved form] | Cancer-related genesDisease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteins | Breast cancerCervical cancerEndometrial cancerFallopian tube cancerLiver cancerLung cancerLymphatic vessel/lymph nodes disorderMesothelial tumourMesothelin positive tumourMetastatic malignant neoplasmMetastatic pleura neoplasmNon-small-cell lung cancerOvarian cancerPancreatic cancerPeritoneal cancerPleural mesotheliomaSolid tumour/cancerStomach cancer | Adhesion and uptake mediationClinical-translation mediationMetabolism mediation | 5 | 0.38 | |||
| MTPN | P58546 | Myotrophin (Protein V-1) | Plasma proteinsPredicted intracellular proteins | Fusion and delivery mediationImmune mediationMetabolism mediation | 5 | 0.38 | ||||
| PAR6A | Q9NPB6 | Partitioning defective 6 homolog alpha (PAR-6) (PAR-6 alpha) (PAR-6A) (PAR6C) (Tax interaction protein 40) (TIP-40) | Plasma proteinsPredicted intracellular proteins | Fusion and delivery mediationReceptor-signaling mediation | 5 | 0.38 | ||||
| PI42A | P48426 | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (EC 2.7.1.149) (1-phosphatidylinositol 5-phosphate 4-kinase 2-alpha) (Diphosphoinositide kinase 2-alpha) (PIP5KIII) (Phosphatidylinositol 5-Phosphate 4-Kinase) (PI5P4Kalpha) (Phosphatidylinositol 5-phosphate 4-kinase type II alpha) (PI(5)P 4-kinase type II alpha) (PIP4KII-alpha) (PtdIns(4)P-5-kinase B isoform) (PtdIns(4)P-5-kinase C isoform) (PtdIns(5)P-4-kinase isoform 2-alpha) | EnzymesMetabolic proteinsPlasma proteinsPredicted intracellular proteins | Fusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.38 | ||||
| RASL3 | Q86YV0 | RAS protein activator like-3 | Predicted intracellular proteinsRAS pathway related proteins | Adhesion and uptake mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 5 | 0.38 | ||||
| SL9A6 | Q92581 | Sodium/hydrogen exchanger 6 (Na(+)/H(+) exchanger 6) (NHE-6) (Solute carrier family 9 member 6) | Disease related genesHuman disease related genesPotential drug targetsPredicted intracellular proteinsPredicted membrane proteinsTransporters | 12 | Clinical-translation mediationFusion and delivery mediation | 5 | 0.38 | |||
| TNR5 | P25942 | Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40) | Cancer-related genesCD markersDisease related genesHuman disease related genesPredicted membrane proteinsPredicted secreted proteins | 1 | Brain cancerCrohn diseaseDiabetes mellitusLupus erythematosusMature B-cell leukaemiaMelanomaMotor neuron diseaseMultiple sclerosisMyasthenia gravisOvarian cancerRheumatoid arthritisSjogren syndromeSolid tumour/cancerThrombocytopeniaThyrotoxicosisTransplant rejection | Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.38 | ||
| UB2D4 | Q9Y2X8 | Ubiquitin-conjugating enzyme E2 D4 (EC 2.3.2.23) (E2 ubiquitin-conjugating enzyme D4) (HBUCE1) (Ubiquitin carrier protein D4) (Ubiquitin-protein ligase D4) | EnzymesMetabolic proteinsPredicted intracellular proteins | Immune mediation | 5 | 0.38 | ||||
| UBE2S | Q16763 | Ubiquitin-conjugating enzyme E2 S (EC 2.3.2.23) (E2 ubiquitin-conjugating enzyme S) (E2-EPF) (Ubiquitin carrier protein S) (Ubiquitin-conjugating enzyme E2-24 kDa) (Ubiquitin-conjugating enzyme E2-EPF5) (Ubiquitin-protein ligase S) | EnzymesMetabolic proteinsPredicted intracellular proteins | Clinical-translation mediationImmune mediationMetabolism mediation | 5 | 0.38 | ||||
| ACM4 | P08173 | Muscarinic acetylcholine receptor M4 | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | AsthmaAttention deficit hyperactivity disorderEye anterior segment structural developmental anomalyGlaucomaNausea/vomitingRespiratory system disease | Clinical-translation mediationReceptor-signaling mediation | 4 | 0.38 | ||
| AKTIP | Q9H8T0 | AKT-interacting protein (Ft1) (Fused toes protein homolog) | Plasma proteinsPredicted intracellular proteins | Fusion and delivery mediation | 4 | 0.38 |